Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2025-12-26 @ 2:32 AM
Study NCT ID:
NCT04847102
Status:
UNKNOWN
Last Update Posted:
2021-11-18
First Post:
2021-04-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Sponsor:
Walvax Biotechnology Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-22
Start Date Type:
ACTUAL
Primary Completion Date:
2021-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-05-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-13
First Submit QC Date:
None
Study First Post Date:
2021-04-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-10
Last Update Post Date:
2021-11-18
Last Update Post Date Type:
ACTUAL